论文部分内容阅读
目的检测Fas、FasL在骨肉瘤中的表达,探讨其生物学意义。方法免疫组化法(SP法)检测41例骨肉瘤和15例正常骨组织中Fas、FasL的表达。结果Fas在骨肉瘤中阳性表达率为53.66%,显著低于正常骨组织中的86.67%(P<0.05);骨肉瘤的病理分级、临床分期较高者Fas表达水平低于较低者(P<0.05)。FasL在骨肉瘤中呈高表达,阳性率为82.93%,高于正常骨组织中的20%(P<0.01)。FasL在骨肉瘤中的表达与其病理分级、临床分期无关(P>0.05)。结论骨肉瘤中Fas/FasL的异常表达可能参与了骨肉瘤细胞的免疫逃避机制。
Objective To detect the expression of Fas and FasL in osteosarcoma and to explore its biological significance. Methods Immunohistochemistry (SP method) was used to detect the expression of Fas and FasL in 41 cases of osteosarcoma and 15 cases of normal bone tissue. Results The positive expression rate of Fas in osteosarcoma was 53.66%, which was significantly lower than that in normal bone tissue (P <0.05). The expression of Fas in osteosarcoma was lower than that in the higher clinical stage (P <0.05). FasL was highly expressed in osteosarcoma, the positive rate was 82.93%, which was higher than that in normal bone tissue (P <0.01). The expression of FasL in osteosarcoma had no correlation with the pathological grade and clinical stage (P> 0.05). Conclusion The abnormal expression of Fas / FasL in osteosarcoma may be involved in the immune evasion mechanism of osteosarcoma cells.